JPMorgan Upgrades Charles River Labs (CRL) to Overweight

Go back to JPMorgan Upgrades Charles River Labs (CRL) to Overweight

Wells Fargo Upgrades Charles River Labs (CRL) to Outperform on Major Sell-Off

December 13, 2012 7:01 AM EST

Wells Fargo upgraded Charles River Labs (NYSE: CRL) from Market Perform to Outperform with a valuation range of $40-$42, saying shares are oversold following Wednesday's 9% swoon on guidance.

The firm comments, "We are upgrading shares of CRL to Outperform from Market Perform following the company's 2013... More

Charles River Labs (CRL) Guides FY13 EPS Below Views

December 12, 2012 7:34 AM EST

Charles River Laboratories International, Inc. (NYSE: CRL) provided guidance for 2013 and reaffirmed guidance for 2012.

James C. Foster, Chairman, President and Chief Executive Officer, said, The actions we have taken in the last three years to enhance our in vivo biology portfolio, improve our operating efficiency, and forge stronger... More